Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

NCT02049905 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

433

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

Interventions

DRUG: Aldoxorubicin
DRUG: Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)

Sponsor

ImmunityBio, Inc.